Tumor Necrosis Factor Inhibitor Drugs Market To Reach $26.6 Billion By 2030

Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends

The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth.

Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market.

The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market.

Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions.

Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July 2023.

 Request a free sample copy or view report summary: Tumor Necrosis Factor Inhibitor Drugs Market Report

Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights

• By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers.

• In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally.

• The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing.

Tumor Necrosis Factor Inhibitor Drugs Market Segmentation

Grand View Research has segmented the global tumor necrosis factor inhibitor drugs market based on product, application, sales channel, and region:

Tumor Necrosis Factor Inhibitor Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)

• Humira

• Enbrel

• Remicade

• Simponi/Simponi Aria

• Cimzia

• Biosimilars

Tumor Necrosis Factor Inhibitor Drugs Application Outlook (Revenue, USD Million, 2018 - 2030)

• Rheumatoid Arthritis

• Psoriasis

• Psoriatic Arthritis

• Ulcerative Colitis

• Crohn’s Disease

• Ankylosing Spondylitis

• Juvenile Idiopathic Arthritis

• Hidradenitis suppurativa

• Others

Tumor Necrosis Factor Inhibitor Drugs Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Speciality Pharmacy

• Online Pharmacy

Tumor Necrosis Factor Inhibitor Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE 

  • Kuwait

List of Key Players in the Tumor Necrosis Factor Inhibitor Drugs Market

• AbbVie Inc.

• Amgen Inc.

• Johnson & Johnson Services Inc.

• UCB S.A.

• Pfizer, Inc.

• Novartis International AG

• Boehringer Ingelheim Pharmaceuticals, Inc.

• Merck & Co., Inc.